Migraine is far more than a headache—it’s a disabling neurological condition that affects millions and drains over $110 billion annually from the U.S. and EU economies through medical costs and lost productivity. Yet, despite its massive impact, current treatment options fall short. Most people with chronic migraine stop using medication within the first year due to side effects or lack of relief. That’s why Salvia BioElectronics, a clinical-stage medical device company, is stepping up with a game-changing solution: neuromodulation therapy for migraine using a minimally invasive, ultra-thin implant designed for real-world use.
The Dutch startup has just closed a $60 million Series B round, bringing its total funding to more than $90 million. The oversubscribed round was led by Innovation Industries, with backing from Invest-NL and the EIC Fund. Existing investors—including Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, BOM, and Thuja Capital—also joined.
The funding will support regulatory approvals, clinical development, and preparation for commercial launch of the company’s flagship product: MySalvia Therapy.
Restoring Control for Chronic Migraine Patients
Salvia’s founders—Hubert Martens (CEO), Daniel Schobben (CTO), and Wim Pollet (CMO)—bring decades of experience in medical devices, having worked at companies like Medtronic, St. Jude, and Philips. Founded in 2017, Salvia’s goal is simple but powerful: give chronic migraine patients their lives back.
Unlike conventional neurostimulation systems, Salvia’s MySalvia Therapy is fully implantable, user-activated, and tailored for the anatomy of the head and neck. It uses two ultra-thin implants—one on the forehead, one on the back of the head—to deliver targeted electrical pulses to nerves associated with migraine.
The system is controlled by a wearable device, letting patients activate treatment on demand with the press of a button. No bulky hardware. No waiting for relief.
In clinical trials, this approach shows promise in reducing both the frequency and severity of migraine attacks. The FDA has already designated Salvia’s system a Breakthrough Device, fast-tracking it for regulatory review.
Pioneering a New Era of Migraine Treatment
Salvia’s therapy is now being tested in the RECLAIM study, a clinical trial evaluating safety and efficacy. With this new funding, the company will accelerate trial completion, pursue FDA approval in the U.S., and seek regulatory clearances in Europe and Australia.
Salvia’s approach stands apart in a growing field. While competitors like Medtronic, Boston Scientific, and Abbott offer neurostimulation for chronic pain, they don’t offer systems designed specifically for migraine. Other migraine-focused devices, such as those from Cefaly and Neurolief, are noninvasive but external—often less precise and harder to integrate into daily life.
Salvia, in contrast, offers a minimally invasive, long-term solution that empowers patients with reliable, on-demand therapy in a discreet form. This makes it one of the most advanced options available for people who’ve failed traditional migraine treatments.
“Chronic migraine isn’t just a medical issue—it’s a quality-of-life crisis,” said Hubert Martens, CEO and co-founder. “Our therapy offers a real path to freedom for people stuck in the cycle of pain, missed work, and medication that doesn’t work. With this funding, we’re moving one step closer to delivering that freedom to millions.”
Leading investor Innovation Industries sees Salvia’s platform as a breakthrough. “Salvia is redefining migraine treatment with a technology-first, patient-first approach,” said Caaj Greebe, Partner at the firm. “They’re not just improving outcomes—they’re giving patients real control, which is the core of any truly innovative therapy.”
Salvia’s strong syndicate of European deep tech investors and health-focused funds shows growing support for bioelectronics in chronic care. The company also plans to explore its technology’s potential to treat cluster headaches and other neurological disorders.
Active in the U.S., Europe, and Australia, Salvia is now building toward commercial readiness with a laser focus on delivering the next standard of care in migraine relief.
